Save time and jump to the most important pieces.
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
10-Q - ULTRALIFE CORP (0000875657) (Filer)
NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation ("Ultralife" or the "Company") (NASDAQ:ULBI) has appointed Michael E. Manna as the Company's President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec will remain with Ultralife as an employee for a sixty-day period ending January 20, 2023 in an advisory role to ensure a smooth leadership transition. In addition to his new role, Mike Manna will retain his leadership position for the Company's Battery & Energy Products segment which he held prior to his appointment as President & CEO. "Over the past twe
NEWARK, N.Y., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) completed its acquisition of all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR) on October 31, 2024. "I am thrilled to welcome Electrochem to the growing Ultralife Team as another valued member that shares our core values, operating philosophy and strong commitment to both our associates and our long-standing customers. Having achieved our target of closing the acquisition of Electrochem by the end of October, we now look forward to working closely with Khristine Carroll, President – Electrochem, and her experienced
NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable
NEWARK, N.Y., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has signed a stock purchase agreement to acquire all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") to include its state-of-the-art ISO certified technology and manufacturing facility for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR), subject to customary working capital adjustments. The transaction is expected to close by the end of October. Ultralife expects to finance the transaction through its primary lender. Based in Raynham, MA and with over forty years of battery technology experience in critical applications, Electrochem designs and manufactures primary li
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
Ultralife (NASDAQ:ULBI) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 57.14 percent. This is a 1200 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $42.98 million which beat the analyst consensus estimate of $42.00 million by 2.34 percent. This is a 34.68 percent increase over sales of $31.92 million the same period last year.
Ultralife Corporation (NASDAQ:ULBI) has been added to the Russell 2000® Index and the broad market Russell 3000® Index as part of the 2024 annual reconstitution of the index, effective at the open of the U.S. equity market today, July 1, 2024.
Benchmark analyst Josh Sullivan maintains Ultralife (NASDAQ:ULBI) with a Buy and raises the price target from $13 to $14.
Benchmark initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)